For instance, in breast cancer, ESR1 mutation detection by ctDNA led to an ORR of 25% (n = 4) with SERD therapy, whereas in ovarian cancer, DNA damage repair gene mutation detection resulted in an ORR of 0% (n = 2) with PARP inhibitors. This evidence concerns the gene ESR1 and breast carcinoma.